Three new morphine-based compounds bearing arginyl moieties, compounds 7, 9a, and 9b, have been synthesized using solid phase and solution phase techniques with the aim of obtaining new transdermal analgesics. Preliminary biological assays have shown that these compounds have a relatively high affinity for opioid receptors, achieving $94 % inhibition of radioligand binding at a concentration of 10 mM in non-selective opioid binding assays. Further testing on two of the analogues, 9a and 9b, demonstrated that these compounds were acting as agonists, rather than antagonists, at the opioid receptors and 9b achieved the significant result of 73 % inhibition of contractile responses in the electrically stimulated guinea pig ileum assay at a concentration of 30 mM. Unfortunately, none of the molecules showed evidence of transdermal activity.
Introduction
Morphine (1) is a commonly used drug for the treatment of chronic pain. [1] Apart from its highly desirous analgesic affect, and despite its wide use, morphine tends to be used with reservation because of the associated side effects. [2] Some of these side effects include sedation, addiction, respiratory depression, nausea, drowsiness, tachycardia, and hypotension, all of which have been shown to be associated with central nervous system (CNS) activity. [3, 4] For many years, morphine was thought to have acted only in the CNS. [5] In the past few decades, however, many studies have shown that morphine and other opioid derivatives are also capable of eliciting a peripheral mode of activity. [5, 6] As most painful conditions are associated with inflammation (e.g., from post-operative pain, pain associated with cancer, burns, arthritis, and trauma), and as inflammation results in a local upregulation of opioid receptors, peripherally acting opioids are a logical choice of analgesic to treat such conditions (Fig. 1 ). [7, 8] Compounds containing a guanidine functionality have previously been shown to prevent blood-brain barrier (BBB) permeation [9] [10] [11] as they protonate to form more hydrophilic salts at physiological pH. [12] This concept has previously been extended to the morphine molecule by our group [10] in order to synthesize a selective, peripherally acting analgesic without the above mentioned side effects.
Work performed by Rothbard et al. found that an arginine heptamer was effective in enabling cyclosporin A to cross through the skin and be absorbed into circulation. [13] The work described in this paper involves the introduction of an argininebased moiety into the morphine molecule through a spacer group at the N-methyl position (see structure 2). In order to reduce the chances of the heptameric arginine residue reducing the binding efficiency at the opioid receptor, simpler molecules containing one or four arginine residues were prepared. Since arginine also contains a guanidine functionality, the attachment of the arginine-based moieties to the morphine derivatives was expected not only to result in an increase in skin permeability, but also in preventing permeation through the BBB.
3,6-Bis(t-butyldimethylsiloxy)-17-(3 0 -chloropropyl)-7,8-didehydro-4,5-epoxymorphinan (3) was prepared by reaction of TBDMS-protected normorphine with 3-bromo-1-chloropropane. 17-(3 0 -Aminopropyl)-3,6-bis(t-butyldimethylsiloxy)-7,8-didehydro-4,5-epoxymorphinan (4) has been synthesized previously by our group (Fig. 2) . [10] These two compounds were used as starting materials for the attachment of the arginyl moiety to the morphine molecule.
Results and Discussion
The arginyl-modified morphine compound 7 was prepared by reaction of Wang-resin attached, 2,2,4,6,7-pentamethyldihydrobenzofurane (Pbf)-protected arginine 5 with the chloro compound 3, and the intermediate 6 was reacted with fluoride ion to remove the tert-butyldimethylsilyl (TBDMS) groups. Cleavage of the compound from the resin with trifluoroacetic acid (TFA) also removed the Pbf group giving the arginylmorphine 7 (Scheme 1).
Compound 7 was characterized by mass spectrometry, and 2D NMR analysis enabled both 1 H and 13 C NMR spectra to be assigned. Interestingly, the protons in the 1 and 2 positions of the morphine moiety were reversed in order in this spectrum relative to that typically observed in most morphine derivatives. This was identified from the 2D NMR scans and the effect was attributed to changing the organic CDCl 3 solvent to the polar D 2 O solvent. A similar reversal was observed in the spectra of all of the other morphine analogues run in D 2 O.
The morphine-arginamide compounds 9a and 9b were prepared as their TFA salts by coupling the amine 4 with either Fmoc-Arg(Pbf)COOH or Fmoc[Arg(Pbf)] 4 COOH using standard peptide synthesis methodology [14] utilizing the coupling reagents (2-(1H-7-aza-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate) (HATU) and N-methylmorpholine (NMM) in a mixture of N,N-dimethylformamide (DMF) and dichloromethane (DCM). The protected products 8a and 8b were then globally deprotected to give 9a and 9b (Scheme 2).
The mass spectrum of the reaction product showed a peak attributable to 8a together with a lower intensity peak. Purification by column chromatography using two types of eluent resulted in 77 % of 8a. Some dibenzofulvene was eluted during column chromatography suggesting that partial Fmocdeprotection had occurred; the resultant Fmoc-deprotected material would then possess high affinity to the stationary phase and resist elution. The product 8a was characterized by mass spectrometry, IR spectroscopy, and C NMR spectra were assigned through the analysis of COSY, HMQC, and HMBC 2D NMR spectra, however, the overlap of peaks meant that many of these signals were recorded as multiplets, and could not be further defined. Preparation of 8b using similar methodology gave a 44 % yield.
The order of protecting group removal was important for efficient purification of the arginamide-substituted derivatives 9a and 9b. The Fmoc group was removed first as the resulting intermediate was soluble in DMF and hence facilitated subsequent silyl and Pbf deprotection. After each deprotection step, the presence of product and absence of starting material was established by TLC, 1 Pure samples of 7, 9a, and 9b were obtained by preparative HPLC but in each case only low recovery from the column was achieved.
Biological and Pharmacological Testing
Samples of 9a and 9b were sent to MDS Pharma Services in Taiwan for opioid binding and guinea pig ileum assays. Because of the limited availability of analogue 7, however, only the selective and non-selective opioid binding studies could be performed (and only at one concentration). A transdermal penetration assay was conducted on morphine analogue 9b.
Non-Selective Binding Studies
All three morphine analogues elicited $94 % inhibition of radioligand binding in rats at a concentration of 10 mM in the non-selective assays. In these assays significant responses were also achieved at lower concentrations of 0.1-10 mM, where there was variation in the binding of each of these compounds. The results of the non-selective studies are shown in Table 1 . The half maximal inhibitory concentration (IC 50 ) values clearly show that the strongest agonist was the morphine-arginamide 9a (IC 50 0.173 mM, the dissociation constant for inhibitor binding (K i ) 0.101 mM), followed by the morphine-tetraarginamide 9b (IC 50 0.386 mM, K i 0.225 mM) and finally the morphine-arginine 7 (IC 50 0.678 mM, K i 0.396 mM). Reference compounds were also tested concurrently with these samples as a comparative measure. Naloxone is the standard reference used by MDS Pharma and this strongly binding antagonist [15] achieved an IC 50 of 1.07 nM in the nonselective assay. In the non-selective assays performed at MDS Pharma, naloxone typically achieves an IC 50 of 1.30 nM, indicating a decline in the average response by 18 %. The IC 50 of morphine was not recorded concurrently with these samples, however, in separately run assays performed in the same manner, MDS Pharma have determined that morphine binds to these receptors with an IC 50 of 3.80 nM. Taking the same variable decline into account, the IC 50 of morphine becomes 3.10 nM, and when compared with the morphine-arginine derivatives, morphine appears to have a higher affinity for the opioid receptors by 50-200-fold.
Selective Binding Studies
All three samples gave positive results in all the assay screenings. For the selective m-and k-assays, both compounds 7 and 9a illustrated a stronger affinity for m-rather than k-receptors. Compounds 7 and 9a exhibited 20 and 22 % inhibition of radioligand binding at the k-receptors, respectively, with both compounds displaying 42 % inhibition at m-receptors. The tetraarginamide compound 9b was found to exhibit contrasting results to the single arginine 7 and arginamide 9a derivatives exhibiting 45 % and 8 % inhibition of radioligand binding in the selective k-and m-assays, respectively.
These results (see Table 2 ) indicate that for these selective receptor tests, there was very little difference in opioid receptor binding whether the arginine attachment was bound to the morphine moiety through the amine or carboxy groups (7 and 9a). However, the attachment of a bulky tetraarginamide moiety, 9b, clearly has an effect on receptor selectively and caused a reversal in the binding affinities for m-and k-receptors to those seen in compounds containing a single arginine.
It has been suggested that morphine's main analgesic effect tends to be associated with activation of the m-receptor, while side effects tend to be more associated with activation of the k-receptor. [16] Activation of m-receptors alone, however, cannot induce analgesia and additional interaction of the drug at other opioid receptors is required. [16, 17] In these preliminary tests, the compounds containing only one arginine group, the 7 and 9a analogues, bind more strongly to the m-receptors than the k-receptors, suggesting that these molecules have potential as opioid analgesics.
Transmurrally Stimulated Guinea Pig Ileum Tissue Assay
The morphine-arginamide compounds 9a and 9b were tested on transmurally stimulated guinea pig ileum at a concentration of 30 mM. At this concentration, 9a and 9b were found to decrease ileum contractions by 21 and 73 %, respectively, in contrast to atropine which achieves 100 % inhibition at this concentration.
Transdermal Study
The ability of the tetraarginamide compound 9b to act transdermally was briefly investigated using dermatome skin. A 0.002 M solution of tetraarginamide 9b was diffused through the skin with a flow rate of 0.5 mL h À1 over a 24 h period. Unfortunately the tests showed no evidence for passage of 9b through the skin.
Conclusion
Three derivatives of morphine 7, 9a, and 9b with covalently bound arginine moieties have been prepared. All three showed significant non-selective binding to opioid receptors but with much less activity than morphine in both non-selective and selective radioligand assays. These analogues also showed less activity than atropine in a transmurrally stimulated guinea pig ileum tissue assay. The molecules showed no transdermal capability. In view of the reduced biological and pharmacological activity relative to morphine, it was decided that attempts to increase the transdermal activity by preparing, for example, a hepta-arginine analogue could not be justified.
Experimental
General Experimental Procedures 1 H and 13 C NMR spectra were recorded on a Bruker Avance DPX 300 spectrometer (operating at 300 and 75 MHz for 1 H and 13 C spectra, respectively) and a Bruker Avance DRX400 spectrometer (operating at 400 and 100 MHz for . IR spectra were recorded on a PerkinElmer 1600 series Fourier Transform infrared spectrometer. Samples were prepared as KBr discs (for solids) or as neat liquids between sodium chloride plates. Mass spectrometry (low-resolution ESI) measurements were run in methanol or a mixture of water/acetonitrile on a Micromass Platform Electrospray mass spectrometer. High-resolution mass spectrometry measurements were run in methanol, or a mixture of water/ acetonitrile, on a Bruker BioApex 4.7 Teltra FT-ICR instrument fitted with an Analytica Electrospray Source at high resolution and calibrated using NaI clusters, or on an Agilent G1969A LC-TOF system with reference mass correction Agilent 1100 Series LC. Melting points (mp) were determined using a Buchi Melting Point B-545 melting point apparatus.
Analytical and preparative reverse phase (RP) HPLC was performed on an Agilent 1100 series instrument equipped with an Agilent 1100 Detector (measuring absorbance at a range of wavelengths between 214 and 280 nm), an analytical column (Waters X-Terra C18 4.6 Â 150 mm 2 , 5 mm) and a preparative column (Vydac C18 22 Â 250 nm 2 , 10 mm). Two solutions were used for measurements, solution A consisting of 0.5 % TFA in water and solution B consisting of 0.5 % aqueous TFA with MeCN (3/7, v/v), with a flow rate of 1 mL min
À1
. All opioid binding assays and transmurrally stimulated guinea pig ileum assays were performed by MDS Pharma, Shanghai according to literature procedures, as described in the results section. HPLC of compound 9b in the transdermal studies used an Agilent 1100 series instrument equipped with an Agilent 1100 Detector, measuring absorbance at a range of wavelengths between 214 and 280 nm, equipped with Waters Deltapak C18 3.9 Â 300 mm 100A 15 mm column, and employing two solutions: solution A consisting of 1 % TFA in water and solution B consisting of 1 % TFA in MeCN (3/7 v/v), with flow rate of 1 mL min
. DMF was purchased from Aldrich and Auspep. 3-((4R,7S,7aR,12bS )-7,9-Dihydroxy-4,4a,7,7a-tetrahydro-1H-4,12 methanobenzofuro[3,2-e] isoquinolin-3(2H)-yl)propyl)amino)-5-guanidinopentanoic Acid (7) Step (i), Fmoc deprotection: [14] Fmoc-Arg(Pbf)-Wang resin (0.20 g, 2.0 mmol g À1 loading, 0.39 mmol) was weighed and placed into a fritted 10 mL plastic syringe with fitted tap. The resin was swollen in DCM (6 mL, 3 Â 1 min, 2 Â 30 min) and washed with DMF (6 mL, 3 Â 1 min, 2 Â 20 min), the solvents being removed by filtration under vacuum between washings. The Fmoc group was removed with 20 % piperidine/DMF (v/v) (6 mL, 1 Â 1 min, 2 Â 20 min) and the resin again washed with DMF (6 mL, 3 Â 1 min, 2 Â 15 min) to ensure all traces of reagents had been removed.
Preparation of 2-((
Step (ii), substitution reaction: KI (0.07 g, 0.39 mmol) followed by triethylamine (0.05 mL, 0.39 mmol) was added to a solution of 3 (0.23 g, 0.39 mmol) in dry DMF (2 mL) and dry -enkephalin, a reference peptide with high m-opioid receptor specificity.
C
The control compound DAMGO is a proprietary compound with selective k-opioid receptor agonist activity.
DCM (2 mL). The H 2 N-Arg(Pbf)-Wang resin prepared above was then added to this solution and the suspension was stirred at ambient temperature for 5 days, and then at 608C for 1 day. Following a negative Kaiser test, the suspension was filtered off and washed with dry DMF (6 mL, 5 Â 1 min), dry DCM (6 mL, 5 Â 1 min), and MeOH (6 mL, 2 Â 10 min). Half of the remaining resin was swollen in dry DCM (6 mL, 1 Â 45 min), collected by filtration, and NH 4 F (0.22 g, 5.88 mmol) in dry MeOH (5 mL) was added followed by the addition of dry DCM (1 mL) and dry DMF (1 mL). The suspension was agitated for 48 h (note: after 24 h the reagents were removed by filtering and replaced with fresh reagents). The resin was then collected by filtration and any remaining NH 4 F removed by successive washing with MeOH (6 mL, 2 Â 1 min), distilled water (6 mL, 2 Â 1 min), DMF (6 mL, 5 Â 1 min), DCM (6 mL, 5 Â 1 min), and MeOH (6 mL, 2 Â 5 min). The resin was then dried under vacuum for 1 h. The material was cleaved from the resin with TFA solution (10 mL) for 6.5 h as described above to give 7 as a pale yellow powder (89 mg 
Preparation of 2-Amino-N-(3-((4R,7S,7aR,12bS)-7,9-dihydroxy-4,4a,7,7a-tetrahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3(2H)-yl)propyl)-5-guanidinopentanamide (9a)
Step (i), coupling reaction: Fmoc-Arg(Pbf)-COOH (0.24 g, 0.37 mmol) and HATU (0.70 g, 1.84 mmol) were partially dissolved in dry DCM (4 mL) and DMF (12 mL). NMM (0.36 mL, 3.31 mmol) was added to the reaction mixture and the yellow solution was quickly added to a stirring solution of 4 (0.20 g, 0.37 mmol) in DCM (5 mL) and DMF (3 mL). After 3 days, the DCM was removed and DMF concentrated to approximately half volume. Sat. aqueous NaHCO 3 solution (20 mL) was added and the product was extracted with DCM (3 Â 15 mL 3420bm, 3348bm, 2932s, 2858m, 1719m,  1627s, 1553s, 1499s, 1449s, 1387m, 1255s, 1168m, 1104s,  1035m, 980m, 843s, 783m, 740m, 669m, 560m . 
Step (ii), Fmoc deprotection: To a solution of 8a (117 mg, 0.098 mmol, as a mixture of ,80 % 8a þ ,20 % tetramethylguanidine by-product [18] ) in DCM, was added 10 equivalent of Et 3 N (141 mL, 1.01 mmol). The mixture was stirred at room temperature overnight under a nitrogen atmosphere. The reaction mixture was then concentrated to give an orange oil which was chromatographed (Al 2 O 3 neutral) using EtOAc/hexane (1/1), EtOAc/hexane/MeOH (4/4/0.5), DCM/MeOH (9/1), and DCM/MeOH/NH 4 OH (9/4/0.4) to afford the Fmoc-deprotected product as a white solid (66 mg, 95 % yield),
Step (iii), silyl [19] and Pbf [14] deprotection: The Fmocdeprotected product from the previous step (0.07 mmol) was dissolved in CH 3 OH (8 mL). NH 4 F (0.24 g, 6.57 mmol) was added and the solution stirred for 2 days under N 2 . The solution was then concentrated under vacuum and the residue triturated with DCM (6 Â 5 mL). The silyl-deprotected product was obtained as a white solid (0.48 g).
. TFA solution (10 mL) was added to the silyldeprotected product and the solution stirred for 4 h as described in the general experimental section. The resulting white solid was dissolved in distilled water (5 mL) and filtered through a Millipore filter (0.45 mM) to give a clear yellow solution which was lyophilized to give 9a as an off-white solid (0.40 g) that was purified by preparative RP-HPLC. Analytical RP-HPLC (Agilent, TSK-gel): Gradient elution of 0-100 % of solution B over 60 min gave the titled product 9a after 46.7 min. Preparative RP-HPLC (WatersTM, TSK-gel): Gradient elution of 0-100 % of solution B over 90 min gave 9a after 45.0 min and the tetramethylguanidine by-product [18] after 48.9 min. The product peaks from the preparative HPLC eluted after 45.0 min and were lyophilized to give 9a as a white powder (9 mg in .99.5 % purity (3 % yield as the TFA salt) and 22 mg in .95 % purity (8 % yield as the TFA salt)). Step ( 16 mmol) in DMF (2 mL) was then added to this mixture. The yellow solution was stirred at ambient temperature for 23 h. Water (7 mL) was then added to the reaction mixture and the product was extracted with DCM (4 Â 7 mL). The combined organic phase was collected and solvent was removed to give the crude material containing product 8b (0.35 g, ,91 
Step (ii), Fmoc deprotection: The unpurified sample of 8b (0.23 g, 0.09 mmol) obtained from the previous reaction was deprotected using 10 equivalent of Et 3 N (0.94 mmol) in DCM (3 mL) and stirred at ambient temperature overnight. The solvent was removed under vacuum and the Fmoc-deprotected product was confirmed by mass spectrometry:
1096.1. The crude product was treated with Et 2 O to give the crude Fmoc-deprotected product as a pale yellow solid.
Step (iii), silyl [19] and Pbf [14] deprotection: The unpurified Fmoc-deprotected product from step (ii) above was deprotected by treating with TFA solution (95 % TFA/2.5 % TIPS and 2. 
. 
Opioid Binding Assays
Selective m-receptor binding assays were performed using methodology described in Wang et al. [20] Selective k-receptor binding assays were performed using methodology described in Macquire et al. and Simonin et al. [21, 22] Non-selective receptor binding assays were performed using methodology described in Pasternak et al. and Childers et al. [23, 24] 
Specific Conditions
The selective k-receptor and m-receptor assays were based on the use of human recombinant HEK-293 cells or human recombinant CHO-K1 cells, cultured to confluency in Gibco defined media supplemented with 5 % fetal bovine serum (FBS) (obtained from Invitrogen Australia Pty Ltd, Mulgrave, Australia), plated by serial two-fold dilution in 96-well plates to a final volume of 200 mL, and incubated at 258C. Cell viability was monitored in duplicate with the MTS reagent [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfo phenyl)-2H-tetrazolium)bromide] in dimethyl sulfoxide (DMSO, 20 mL), in the presence of phenazine methosulfate (PMS), using a 100 mL aliquot of the cultured cells. This mixture was incubated at 258C for 2 h and then cell viability was determined by measurement of the absorbance at 490 nm. These results indicated an optimal plating density of 3000 cells well
À1
for subsequent compound screening.
For the selective k-receptor and m-receptor assays tests, compounds 7, 9, and 9b at appropriate concentrations in the presence of 0.6 nM [ 3 H]diprenorphine in 1 % (v) DMSO and 20 mM or 50 mM TRIS-HCl buffer, pH 7.4, were added to the cultured cell samples, which were then incubated at 258C for 60 min. Control experiments without the test compound(s) or using 10 mM naloxone as the non-specific ligand were similarly performed. The non-selective assay was based on the use of Wistar rat brain cells with the test compounds 7, 9, and 9b at appropriate concentrations in the presence of 1 nM [ 3 H]naloxone in 1 % (v) DMSO and 50 mM TRIS-HCl buffer, pH 7.4, incubated for 40 min at 258C. For the non-specific assay, 1 mM naloxone was employed as the control non-specific ligand. The corresponding dissociation constant (K d ), the maximum binding capacity (B max ), and specific binding values for the k-, m-, and non-specific assays were derived from the test and control inhibition curves, and the inhibitory activity expressed in terms of pmol ligand per mg of protein. All assays were performed in duplicate.
Transmurally Stimulated Guinea Pig Ileum Assay
The transmurally stimulated guinea pig ileum assays were performed using methodology described by Moritoki et al. [25] The process involved the single injection of the compound (30 mM) into an organ bath containing transmurally stimulated Dunkin Hartley guinea pig ileum (325 AE 25 g) immersed in Krebs buffer solution, 1 mM methylsergide-treated with pH 7.4 at 328C. After 5 min, the reduction of neurogenic twitch relative to 0.3 mM atropine was measured.
Transdermal Study
The diffusion studies were performed in modified flow-through diffusion cells (1 cm   2 ) with the temperature maintained at 32 AE 18C. Permeation studies were conducted using eight separated cells with excised human dermatome 500 mm skin (supplied by Acrux Ltd, Dec 2010), and degassed MilliQ water as a receptor fluid.
A reference cell was loaded with 285 mL of MilliQ water and the remaining cells with 285 mL of 9b (2 mg mL À1 concentration). The receptor fluid was added over 24 h with a flow rate of 0.5 mL h À1 and samples collected at four hourly intervals.
The individual four hourly eluants were analyzed using RP-HPLC but showed no evidence of compound 9b. The total eluants from the seven cells were then combined and the water removed using a freeze dryer. Again HPLC analysis showed no evidence for the presence of compound 9b.
